Simmons Bank Has $5.12 Million Holdings in GSK plc (NYSE:GSK)

Simmons Bank trimmed its holdings in shares of GSK plc (NYSE:GSK) by 1.3% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 151,322 shares of the pharmaceutical company’s stock after selling 1,997 shares during the period. Simmons Bank’s holdings in GSK were worth $5,118,000 as of its most recent SEC filing.

Several other institutional investors have also recently bought and sold shares of the business. FMR LLC raised its stake in shares of GSK by 8.3% in the third quarter. FMR LLC now owns 29,008,928 shares of the pharmaceutical company’s stock worth $1,185,885,000 after acquiring an additional 2,224,345 shares during the last quarter. Fisher Asset Management LLC increased its holdings in shares of GSK by 4.9% in the third quarter. Fisher Asset Management LLC now owns 18,576,930 shares of the pharmaceutical company’s stock valued at $759,425,000 after purchasing an additional 870,449 shares in the last quarter. Hotchkis & Wiley Capital Management LLC raised its position in GSK by 30.8% in the 3rd quarter. Hotchkis & Wiley Capital Management LLC now owns 3,542,143 shares of the pharmaceutical company’s stock worth $144,803,000 after purchasing an additional 833,080 shares during the last quarter. Miller Howard Investments Inc. NY bought a new position in GSK in the 4th quarter valued at $23,366,000. Finally, Bridgewater Associates LP boosted its position in GSK by 107.3% in the 3rd quarter. Bridgewater Associates LP now owns 965,836 shares of the pharmaceutical company’s stock valued at $39,483,000 after buying an additional 500,010 shares during the last quarter. Institutional investors own 15.74% of the company’s stock.

GSK Stock Up 3.5 %

GSK stock opened at $38.39 on Wednesday. GSK plc has a fifty-two week low of $31.72 and a fifty-two week high of $45.92. The company has a debt-to-equity ratio of 1.12, a current ratio of 0.78 and a quick ratio of 0.52. The firm has a market capitalization of $79.56 billion, a price-to-earnings ratio of 24.14, a PEG ratio of 1.12 and a beta of 0.64. The company’s 50 day simple moving average is $34.76 and its 200 day simple moving average is $37.30.

GSK (NYSE:GSK) last announced its quarterly earnings results on Wednesday, February 5th. The pharmaceutical company reported $0.59 earnings per share for the quarter, topping analysts’ consensus estimates of $0.44 by $0.15. GSK had a net margin of 8.13% and a return on equity of 48.59%. As a group, sell-side analysts anticipate that GSK plc will post 4.14 EPS for the current year.

GSK Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Thursday, April 10th. Stockholders of record on Friday, February 21st will be given a dividend of $0.3932 per share. The ex-dividend date of this dividend is Friday, February 21st. This represents a $1.57 dividend on an annualized basis and a dividend yield of 4.10%. This is a positive change from GSK’s previous quarterly dividend of $0.39. GSK’s dividend payout ratio (DPR) is currently 98.74%.

Analyst Ratings Changes

Several equities analysts have recently issued reports on GSK shares. Guggenheim lowered GSK from a “buy” rating to a “neutral” rating in a research note on Thursday, October 31st. Morgan Stanley initiated coverage on shares of GSK in a research report on Wednesday, February 12th. They set an “equal weight” rating on the stock. StockNews.com upgraded shares of GSK from a “buy” rating to a “strong-buy” rating in a research report on Friday, February 7th. Jefferies Financial Group lowered shares of GSK from a “buy” rating to a “hold” rating and cut their price objective for the company from $53.00 to $39.50 in a report on Tuesday, November 12th. Finally, Deutsche Bank Aktiengesellschaft lowered shares of GSK from a “buy” rating to a “hold” rating in a report on Friday, November 15th. Seven analysts have rated the stock with a hold rating and four have given a strong buy rating to the company’s stock. Based on data from MarketBeat, GSK currently has a consensus rating of “Moderate Buy” and a consensus target price of $43.25.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.